Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques

• Main Authors: Mayuresh M. Abhyankar (Author), Feifan Xu (Author), Deborah Chavez (Author), Anna Goodroe (Author), Elda Mendoza (Author), Christopher Chen (Author), Dhiraj K. Singh (Author), Fernando Varnador (Author), Sandra J. Sivananthan (Author), Robert Kinsey (Author), William R. Lykins (Author), Brynn M. Murphy (Author), Andrew R. Martin (Author), Mark A. Tomai (Author), Soutik Ghosal (Author), Corey Casper (Author), Karl Pedersen (Author), William A. Petri (Author), Christopher B. Fox (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Entamoeba histolytica, the causative agent of amebiasis, is one of the top three parasitic causes of mortality worldwide. However, no vaccine exists against amebiasis. Using a lead candidate vaccine containing the LecA fragment of Gal-lectin and GLA-3M-052 liposome adjuvant, we immunized rhesus maca...